Literature DB >> 19017986

Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis.

Sylvie Bertholet1, Gregory C Ireton, Maria Kahn, Jeffrey Guderian, Raodoh Mohamath, Nicole Stride, Elsa M Laughlin, Susan L Baldwin, Thomas S Vedvick, Rhea N Coler, Steven G Reed.   

Abstract

Development of a subunit vaccine for Mycobacterium tuberculosis (Mtb) depends on the identification of Ags that induce appropriate T cell responses. Using bioinformatics, we selected a panel of 94 Mtb genes based on criteria that included growth in macrophages, up- or down-regulation under hypoxic conditions, secretion, membrane association, or because they were members of the PE/PPE or EsX families. Recombinant proteins encoded by these genes were evaluated for IFN-gamma recall responses using PBMCs from healthy subjects previously exposed to Mtb. From this screen, dominant human T cell Ags were identified and 49 of these proteins, formulated in CpG, were evaluated as vaccine candidates in a mouse model of tuberculosis. Eighteen of the individual Ags conferred partial protection against challenge with virulent Mtb. A combination of three of these Ags further increased protection against Mtb to levels comparable to those achieved with bacillus Calmette-Guérin vaccination. Vaccine candidates that led to reduction in lung bacterial burden following challenge-induced pluripotent CD4 and CD8 T cells, including Th1 cell responses characterized by elevated levels of Ag-specific IgG2c, IFN-gamma, and TNF. Priority vaccine Ags elicited pluripotent CD4 and CD8 T responses in purified protein derivative-positive donor PBMCs. This study identified numerous novel human T cell Ags suitable to be included in subunit vaccines against tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19017986      PMCID: PMC2586986          DOI: 10.4049/jimmunol.181.11.7948

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  41 in total

Review 1.  TB subunit vaccines--putting the pieces together.

Authors:  Peter Andersen; T Mark Doherty
Journal:  Microbes Infect       Date:  2005-04-14       Impact factor: 2.700

Review 2.  Tuberculosis subunit vaccine design: the conflict of antigenicity and immunogenicity.

Authors:  Suraj B Sable; Mamta Kalra; Indu Verma; G K Khuller
Journal:  Clin Immunol       Date:  2007-01-05       Impact factor: 3.969

Review 3.  Exploiting immunology and molecular genetics for rational vaccine design against tuberculosis.

Authors:  S H E Kaufmann; S Baumann; A Nasser Eddine
Journal:  Int J Tuberc Lung Dis       Date:  2006-10       Impact factor: 2.373

4.  Tuberculosis vaccines - an update.

Authors:  Peter Andersen
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

Review 5.  Adjuvant activity of CpG oligodeoxynucleotides.

Authors:  Dennis M Klinman
Journal:  Int Rev Immunol       Date:  2006 May-Aug       Impact factor: 5.311

6.  Selection of novel TB vaccine candidates and their evaluation as DNA vaccines against aerosol challenge.

Authors:  Julia Vipond; Richard Vipond; Emma Allen-Vercoe; Simon O Clark; Graham J Hatch; Karen E Gooch; Joanna Bacon; Toby Hampshire; Helen Shuttleworth; Nigel P Minton; Karen Blake; Ann Williams; Philip D Marsh
Journal:  Vaccine       Date:  2006-06-05       Impact factor: 3.641

Review 7.  Tuberculosis vaccine development; from mouse to man.

Authors:  Steven Reed; Yves Lobet
Journal:  Microbes Infect       Date:  2005-04-14       Impact factor: 2.700

Review 8.  Advances in tuberculosis vaccine strategies.

Authors:  Yasir A W Skeiky; Jerald C Sadoff
Journal:  Nat Rev Microbiol       Date:  2006-06       Impact factor: 60.633

Review 9.  Vaccines for tuberculosis: novel concepts and recent progress.

Authors:  T Mark Doherty; Peter Andersen
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

10.  An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis.

Authors:  Laleh Majlessi; Marcela Simsova; Zdenka Jarvis; Priscille Brodin; Marie-Jésus Rojas; Cécile Bauche; Clémence Nouzé; Daniel Ladant; Stewart T Cole; Peter Sebo; Claude Leclerc
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

View more
  80 in total

1.  Mycobacterium tuberculosis PPE60 antigen drives Th1/Th17 responses via Toll-like receptor 2-dependent maturation of dendritic cells.

Authors:  Haibo Su; Zhen Zhang; Zijian Liu; Baozhou Peng; Cong Kong; Honghai Wang; Zhi Zhang; Ying Xu
Journal:  J Biol Chem       Date:  2018-05-08       Impact factor: 5.157

Review 2.  Antigens for CD4 and CD8 T cells in tuberculosis.

Authors:  Cecilia S Lindestam Arlehamn; David Lewinsohn; Alessandro Sette; Deborah Lewinsohn
Journal:  Cold Spring Harb Perspect Med       Date:  2014-05-22       Impact factor: 6.915

3.  Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate.

Authors:  Hillarie Plessner Windish; Malcolm S Duthie; Ayesha Misquith; Greg Ireton; Elyse Lucas; John D Laurance; Remy H Bailor; Rhea N Coler; Steven G Reed
Journal:  Vaccine       Date:  2011-08-02       Impact factor: 3.641

4.  Protection against Mycobacterium leprae infection by the ID83/GLA-SE and ID93/GLA-SE vaccines developed for tuberculosis.

Authors:  Malcolm S Duthie; Rhea N Coler; John D Laurance; Lucas H Sampaio; Regiane M Oliveira; Ana Lucia M Sousa; Mariane M A Stefani; Yumi Maeda; Masanori Matsuoka; Masahiko Makino; Steven G Reed
Journal:  Infect Immun       Date:  2014-07-14       Impact factor: 3.441

Review 5.  Development of new vaccines and drugs for TB: limitations and potential strategic errors.

Authors:  Ian M Orme
Journal:  Future Microbiol       Date:  2011-02       Impact factor: 3.165

Review 6.  Infect and Inject: How Mycobacterium tuberculosis Exploits Its Major Virulence-Associated Type VII Secretion System, ESX-1.

Authors:  Sangeeta Tiwari; Rosalyn Casey; Celia W Goulding; Suzie Hingley-Wilson; William R Jacobs
Journal:  Microbiol Spectr       Date:  2019-05

7.  Interferon γ and Tumor Necrosis Factor Are Not Essential Parameters of CD4+ T-Cell Responses for Vaccine Control of Tuberculosis.

Authors:  Mark T Orr; Hillarie Plessner Windish; Elyse A Beebe; David Argilla; Po-Wei D Huang; Valerie A Reese; Steven G Reed; Rhea N Coler
Journal:  J Infect Dis       Date:  2015-01-30       Impact factor: 5.226

8.  Proteome-scale antibody responses and outcome of Mycobacterium tuberculosis infection in nonhuman primates and in tuberculosis patients.

Authors:  Shajo Kunnath-Velayudhan; Amy L Davidow; Hui-Yun Wang; Douglas M Molina; Vu T Huynh; Hugh Salamon; Richard Pine; Gerd Michel; Mark D Perkins; Liang Xiaowu; Philip L Felgner; JoAnne L Flynn; Antonino Catanzaro; Maria L Gennaro
Journal:  J Infect Dis       Date:  2012-06-25       Impact factor: 5.226

9.  Exploration of novel cellular and serological antigen biomarkers in the ORFeome of Mycobacterium tuberculosis.

Authors:  Liguo Liu; Wei-jia Zhang; Jianhua Zheng; Hua Fu; Qi Chen; Zongde Zhang; Xinchun Chen; Boping Zhou; Lu Feng; Haiying Liu; Qi Jin
Journal:  Mol Cell Proteomics       Date:  2014-01-21       Impact factor: 5.911

10.  Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate.

Authors:  Susan L Baldwin; Valerie A Reese; Po-Wei D Huang; Elyse A Beebe; Brendan K Podell; Steven G Reed; Rhea N Coler
Journal:  Clin Vaccine Immunol       Date:  2015-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.